Protecting the platform

Fusion Antibodies Plc (LSE:FAB) has historically earned most of its Revenue by providing antibody engineering services to drug developers. More recently, it has been trying to turn its own technology into licensable intellectual property. The clearest example is OptiMAL, an antibody library platform it launched commercially in December 2025. On 9 September 2026, the company announced a Patent grant for OptiMAL in Canada. This article looks at how Fusion is building patent protection around the platform, and why that matters given its finances.

What Fusion Antibodies does

Fusion is an AIM-quoted contract services organisation that helps pharmaceutical and biotechnology customers discover, humanise and optimise antibodies. Its services cover antibody discovery, humanisation and optimisation. Alongside this work, it is developing proprietary platforms and a designed-antibody range branded "Opti", with the aim of acting as a technology licensor as well as a service provider. Chief executive Adrian Kinkaid leads the business.

The Canadian patent announced on 9 September 2026

The company said Canadian patent CA 3115150, titled "Antibody Library and Method", was granted on 9 September 2026. According to the announcement, OptiMAL is a proprietary antibody library platform for therapeutic and diagnostic applications, addressing antibody discovery, affinity maturation and sequence optimisation. The patent covers two families of antibodies and the method for the design of such libraries, and complements the company's "Opti" designed antibody offerings. Applications are also in progress in Europe and China.

In its final results, Fusion said OptiMAL had already been patented in Japan and had received acceptance in Australia, alongside the Canadian progress, and that it has been validated by the US National Cancer Institute.

Financial results

On 15 September 2026, Fusion published a replacement version of its results for the year to 31 March 2026, correcting the gross Margin figure to 58.3% from the 53% stated a day earlier. That compares with a gross margin of 22% in the previous year. Revenue rose 7% to £2.1 million, although underlying service revenue fell 5% to £1.86 million. Revenue included £250,000 from an antibody intellectual property transfer to Finn Therapeutics. Second-half revenue was 21% higher than the first half. The operating loss narrowed to £1.13 million from £1.63 million, and the loss after tax was £1.149 million.

Cash at the year end was £1.04 million, up from £0.36 million, after a £1.4 million fundraising in January 2026 at 13p per share. Kinkaid said he was particularly encouraged by the improvement in service revenues during the second half.

Risks and what to watch

The company disclosed a material uncertainty over going concern, saying additional funding is required during the assessment period. It also said first-half FY27 performance has been adversely affected by difficult market conditions, as global financial instability weighs on the healthcare sector. Patents protect technology, but they do not ensure licensing income; the value of OptiMAL will depend on customers adopting it. Other developments include a grant-funded DR5 antibody programme with Queen's University Belfast, expected to deliver a pre-clinical asset by late FY27, and collaborations involving AI and machine learning, including an ongoing project with a US-based AI and Machine Learning Business using Fusion's Mammalian Display platform and a joint project with Oxford University. The company has also said it aims to expand in North America and broaden its customer base, which, if achieved, would help diversify its revenue across more customers and regions.

Conclusion

Fusion is building patent protection around OptiMAL country by country, with the Canadian grant adding to Japan and Australia and further applications pending in Europe and China. This supports its plan to earn licensing revenue from proprietary technology. However, the company remains small, loss-making and in need of more funding, so commercial uptake of the platform will determine whether that protection translates into income.